The partner in your drug discovery, bridging the - Cellvax

1/20
Confidential
Updated: Jan 2014
The partner in your drug discovery,
bridging the gap between R&D and
clinical applications
I. Major Activity
Cellvax SAS, French SME founded in 2001, is a service company (CRO) which
provides complete preclinical innovating services allowing accelerating the drug
development process for unmet needs related to severe human diseases, mainly
in Oncology and Osteoarthritis fields.
II. Mission
Cellvax’s main expertise: in vitro testing, original animal models in Oncology
and Osteoarthritis fields, both subcutaneous (S.C.) and orthotopic tumor models,
induced and spontaneous Osteoarthritis models, toxicity, bio-distribution,
PK/PD studies, in vivo imaging, histological analysis, etc., allowing speeding up
the development of your drug candidates and exploring their maximum potential
and mechanism of actions.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
2/20
Confidential
Cellvax’s competitive advantages: networking, Original animal models in
rodents & non-rodents (Mice, Rats, Hamsters, Guinea pigs, Rabbits, Cats, Dogs,
…); Numerous technical platforms, Reactivity, Confidentiality, Reliability,
Track records of our founder team, etc.
Cellvax positioning in drug discovery process:
Clinical trails
Candidate molecule
identification
Pre-clinical
trials
Phase I
Phase II
Phase III
Phase IV
Commercialization
Drug surveillance
Preclinical tests
Our services allow speeding up the development of your drug candidates,
valorizing drug potential and decreasing the cost of your drug development.
III. Cellvax presentation
Cellvax, founded in 2001, is a fast-growing technology-driven pre-clinical
service company focalizing on oncology and on Osteoarthritis. Today, Cellvax
directly employs and through R&D collaborations motivated and differently
skilled scientists and engineers, working in interdisciplinary teams on several
innovative products.
Since its foundation, Cellvax has significantly progressed as a service company,
especially in different cancer models in mice, angiogenesis models in vitro and
in vivo. Recently, we have developed several other models such as Oncology,
Osteoarthritis, Parkinson diseases, Diabetes, AMD, etc. in order to fully satisfy
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
3/20
Confidential
the specific needs of our customers. We have concluded numerous contracts
with different companies in France, in Europe and in the world.
Here is a brief summary of Cellvax since its foundation in 2001:
1er
French
Government
Grant, OSEO
EU
EUREKA
EU FP-7
projects
New facility,
Multiple
animal species
3. Consolidation &
Expansion
2. Strong
growth
Early phases
clinical trials
Foundation
2001
1. Initiation
2004
2006
2007
2008
2010
Cellvax is always ready to adapt to the market evolution and to satisfy its
customers’ specific needs all over the world. Cellvax is strongly willing to
develop and enhance its national and international collaboration with public
laboratories, biotechnological companies and pharmaceutical companies in
cancer field. In this regard, Cellvax is also actively involved in different
European collaborative programs.
In 2007, Cellvax has successfully launched an EUREKA project in cancer field
named “Oligoclonics Σ!3942” entitled “An innovative technology and product
platform for improved antibody therapeutic” with another French partner (anticancer center: Institut Gustave Roussy) and three partners from Holland. Under
this project, Cellvax has alrealy demonstrated its coordination and managerial
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
4/20
Confidential
skills within a European collaborative R&D environment and through its relation
with the Eureka Office and French funding body.
In 2011, Cellvax has successfully obtained a 2nd FP-7 grant “Piedpiper” for a
total amount of 2.4 millions €.
IV. Main Advantages
Cellvax’s project is founded by scientists and experts. Cellvax’s team is
composed of people who have a strong professional complementary which gives
a scientific, medical and industrial dimension of the company.
Our services are built on these advantages:
A. Present knowledge of Cellvax’s team
The new knowledge progress and the technological explosion in cellular and
molecular biology and genomics have helped tumors molecular detailed
analysis. Cellvax’s team totally controls these knowledges and the related
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
5/20
Confidential
technologies in this field. Our services allow developing a therapeutic approach
which is more suitable for each patient and each biological target.
In order to expand our offers, Cellvax has recently moved to a new laboratory
facility, on the border of Paris, inside “Ecole Nationale Vétérinaire de Maisons
Alfort” (ENVA). The ENVA is one of the oldest and largest veterinary
universities in Europe, created in 1766 just on the border of Paris, with an easy
access by subway. In this new facility, Cellvax is able to provide a number of
new services especially with large animals (Mice, Rats, Hamsters, Guinea pigs,
Rabbits, Cats, Dogs, …), Numerous technical platforms, in vivo imaging platforms, MRI, Scanner, Scintigraphy radio-labeled compounds, etc. In
consequence, Cellvax is able to provide the services not only in small animals,
but also in large animals in a more efficient way.
B. Our multidisciplinary expertise
Cellvax has a network of collaborations and is able to analyze tumoral and blood
biopsies in molecular biology. This network is composed of chemists, molecular
and cellular oncologists, immunologists, doctors, pharmacologists…
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
6/20
Confidential
V. Preclinical Study Services
1). Anti-proliferative tests in vitro
Cellvax proposes in their services to realize different tests in vitro on established
cell lines or primary cultures: anti-proliferative tests, PK study, cell cycle,
apoptosis, etc. This technique allows at first to evaluate the anti-tumoral
potential of drug candidates. Our company has also an important expertise in a
three-dimensional cell culture method of cancer cells called nodules which has
the advantage of maintaining some of the in vivo cellular architecture and
interactions.
2). Original Nodule model in vitro
For anti-cancer drug validation studies in vitro and in vivo, several models have
been developed and used. Here, Cellvax has successfully developed a new
model which is between in vitro and in vivo model, called “the Nodule model in
three dimensions”. We believe that this model could be an ideal tool in anticancer drug discovery studies.
A three-dimensional cell co-culture method is presented where cancer cells can
be maintained alone or combined with other cell types in long-term culture in
order to reconstitute some of the interactions between the different cell elements
in tumors in vivo. The cells are accumulated by centrifugation to form “nodules”
which are cultivated on a semi-solid agar medium at medium / air interface. The
nodules are not only cell aggregates, they are able to develop morphological and
functional differentiation often lost in mono-layer cell culture conditions. Also, a
different sensitivity to chemical and physical anti-tumoral treatments has been
demonstrated. Studies on short-term and long-term effects of anti-cancer
treatments are possible.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
7/20
Confidential
3). Animal cancer models
Today, cancers still remain a major public health problem in the world,
especially in industrialized countries. Cancer is projected to become the leading
cause of death worldwide in the year 2010, according to a new report the
International Agency for Research on Cancer (IARC), a division of the World
Health Organization (WHO). Furthermore, apart from being a public health
burden, the economical facts are as impressive. The costs for cancer care in the
EU sums 54 billion € and the global oncology market is around 40 millions €
with more than 150 cancer drugs approved for its use across the world.
We propose not only subcutaneous tumor models but also original orthotopic
tumor models in animal in which we induce lung cancer, colon cancer, pancreas
cancer, prostate cancer, breast cancer, gastric cancers, brain tumors, leukemia…
The orthotopic tumor models present a degree of complexity superior to
classical pathological models. The implantation of tumor cells in their original
tissue allows development of tumor comparable to human tumor with
production of metastasis in a few weeks. Moreover, the same time course of
development of tumor and metastasis than human is observed in animal.
The tumor development can be induced in animals either by injecting human
and/or rodent tumor cells or by grafting freshly operated human tumors in
animals.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
8/20
Confidential
Metastasis
Blood vessel
The tumor development can be induced in animals either by injecting human
and/or rodent tumor cells or by grafting freshly operated human tumors in
animals.
In vivo perfusion
Surgical operation with specific injections
Stereotaxic injection
Injectin into carotine
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
9/20
Confidential
4). Angiogenic tests in vitro & in vivo
Angiogenesis plays an important role in the tumoral development. Cellvax
proposes pro- or anti-angiogenic tests. In this in vitro model, human umbilical
vein endothelial cells are coated on microcarrier beads then the blood capillaries
formation is analysed. In order to exploit the anti-angiogenic potential of drug
candidates, our test is essential for biotechnology societies which develop these
drug candidates. An in vivo original model is also available and consists on a
Matrigel implantation in mouse and on a measure of the drug candidates’ effects
on the microvessels formation.
Fibrin gel
5). Tumoral invasion tests in vitro
Metastasis formation is the most deleterious mechanism in the tumor formation.
Cellvax proposes in vitro tests which allow to measure the anti-metastatic
potential of drug candidates. These techniques allow to study the intravasation
and extravasation potentials of tumor cells through endothelium. The
intravasation of tumor cells through endothelium is measured by a co-culture
technique. Tumor cells were cultured on a micropore membrane in the top part
of the chamber and endothelial cells were cultured in the low part of the
chamber. This technique consists on measuring the number of tumor cells which
have migrated through the micropore membrane toward to endothelial cells. The
extravasation technique consists on measuring under flow tumor cells adhesion
on endothelial cells.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
10/20
Confidential
6). Tumoral invasion tests in vivo
Cellvax proposes analyses of tumor cells distribution in all animals. Stained
tumor cells can be detected, counted and located in alive animals. This technique
allows determining the anti-metastatic potential of drug candidates.
7). Orthotopic tumor models
Many studies have tested anti-proliferative effect and cancer specificity of drug
candidates in vitro. According to NCI recommendations, selected in vitro
molecules must demonstrate their efficiency on xenografted tumor cell lines in
nude mice, before pre-clinical and clinical development. In this model, tested
molecules are often administered intra-peritonealy. Efficiency of drug
candidates is determined based on the tumor growth inhibition after treatment,
or total tumor regression.
It has been established that subcutaneous tumors in mice don’t metastasize and
develop around the injection. Further studies shown that the subcutaneous tumor
chemotherapy sensitivity can be modified.
To solve this problem, orthotopic xenografts (in origin site) in mice have been
fully developed at Cellvax.
The orthotopic tumor model presents a superior complexity degree compared to
classical models. In fact, tumor cell lines implantation in their origin site allows
the tumoral development comparable to human tumoral development with
metastases formation in a few weeks. This model also allows mimicking
sequential tumor development. The primary tumor develops in its origin site and
metastasizes at distance. The metastasis formation is induced with the similar
order as in human. Cellvax proposes to realise orthotopic models for your drug
validation studies in breast cancer, colon cancer, lung cancer, pancreas cancer,
kidney cancer, prostate cancer, melanoma, glioblastoma, …
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
11/20
Confidential
Lung metastasis induced by human breast tumor cells in mice.
Metastasis
Blood vessel
Lung metastasis induced by mouse breast cancer cells 4T1 in mice.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
12/20
Confidential
8). Syngeneic tumor models in animals
The role of the host immune response in combating neoplastic growth has been
extensively studied over the past several years. In order to investigate the antitumor actiovity of a test compound in a closer situation to human, it is extremely
usual to employ syngeneic immuno-competent animal tumor models for the
preclinical evaluation of test agents. For this purpose, we have developed
different syngeneic tumor models:
-
Leukemia:
Leukemia FBL-3 cells in C57/BL6 mice;
-
Melanoma:
B16F10 tumor cells in C57/BL6 mice;
-
Bladder cancer:
MB49 tumor cells in C57/BL6 mice;
-
Prostate cancer:
TRAMP-C2 tumor cells in C57/BL6 mice;
-
Pancreatic tumor:
PANC02 tumor cells in C57/BL6 mice;
-
Kidney cancer:
RENCA tumor cells in Balb/c mice;
-
Fibrosarcoma:
CSA1M tumor cells in Balb/c mice;
-
Breast cancer:
4T1 tumor cells in Balb/c mice;
-
Brain tumor:
9L in Fisher rats;
-
Colon cancer:
CT26 tumor cells in Balb/c mice;
-
Pancreatic tumor:
PC-1.0 tumor cells in Syrian hamsters;
-
Mastocytoma:
P-815 cells in DBA/2;
-
Hepatic Cancer:
Hepa 1-6 cells in C57/BL6 mice, and
Hepa129 cells in C3H mice;
-
Etc.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
13/20
Confidential
9). Original drug-resistant tumor models in vitro & in vivo
Intrinsic or acquired tumor-mediated drug resistance is a major clinical problem
that can result in the lack of tumor response to chemotherapy. In order to
continuously improve the quality and the originality of Cellvax’s oncology
services, we have successfully established several drug-resistant tumor models:
lung cancer, pancreatic tumor, ovary cancer, etc.
10). In vivo imaging in alive animals
For these studies, we can propose several imaging technologies: PET Scan,
Scanner, X-ray, MRI, Bioluminescence. The new technology, PET (Positron
Emission Tomography) Scan, by labeling with 18FDG (Fluoro-Deoxy-dGlucose), allows to observe phenomenon (micro-metastasis formation, drug biodistribution, etc) in the same alive animal at different time points without
sacrificing animals.
Metastasis
11). Primary tumor cells
Testing your promising compounds by using human primary tumor cells is the
closest way to the real clinical situation. These data would be very useful for
your future clinical trials. The established tumor cell lines, after numerous
passages in vitro, might loose their initial biological characteristics. In contrast,
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
14/20
Confidential
these primary tumor cells (freshly established from human biopsies) conserve
these biological characteristics and could be an ideal tool in anti-cancer studies.
12). More relevant tumor models
-
Direct implantation of human tumor biopsies in mice
To reconstitute tumor micro-environment;
To be as close as possible to human tumors;
Tumors are maintained from mice to mice, without using
cell culture system.
-
Non-rodent cancer models, spontaneous tumors
13). Osteoarthritis animal models
Knee osteoarthritis (OA) affects an estimated 27 million Americans (Lawrence
R.C., et al. Part II,” Arthritis & Rheumatism, vol. 58, no. 1, pp. 26–35, 2008).
Despite extensive research seeking therapeutic interventions for this disease,
there are still no proven disease-modifying treatments for osteoarthritis. With the
number of total knee arthroplasties growing each year, this is a rapidly expanding
public health epidemic, both in terms of health-related quality of life and
financial expenditure (Losina E, et al. The Journal of Bone & Joint Surgery A,
vol. 94, no. 3, pp. 201 – 207, 2012).
For this disease, Cellvax can propose two types of animal models:
Induced Osteoarthritis (OA) Animal Models:
-
Anterior Cruciate Ligament Transection (ACLT) in rabbits, rats, dogs, … ;
Meniscectomy;
Patellectomy;
Immobilization;
Ovariectomy: Postmenopausal OA;
Enzymatic / chemically induced OA;
Others, …
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
15/20
Confidential
Spontaneous Osteoarthritis (OA) Animal Models:
- Mouse (DBA/1, STR/ORT, C57BL/6, C57);
- Guinea pig (Hartley, Duncan-Hartley);
- Others, …
14). Toxicity studies in vivo (both rodent and non-rodent)
A complete toxicity experiment can be proposed at Cellvax in both rodent and nonrodents:
-
Acute toxicity in mice, animals;
Sub-acute toxicity in animals;
Chronic toxicity in animals;
MTD (Maximum Tolerated Dose) with single dose and/or repeated doses;
“Abnormal toxicity” in two animal species according to European guidelines;
Complete blood count (CBC). (Total blood analysis: Red cells; White cells;
Platelets; Hemoglobin) and Chemistry profile (Alanine aminotransferase
(ALT); Aspartate aminotransferase (AST); Alkaline phosphatase (ALP);
Creatinine kinase; Glucose);
- Monitoring: animal body weight, behavior, eventual death;
- Hematological and biochemical analysis;
- Macroscopic observation and histological analysis on main organs.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
16/20
Confidential
15). Bio-distribution and PK studies in vivo (both rodent and nonrodent)
In order to understand the pharmacokinetics (PK) of your innovating drugs, we
propose a bio-distribution and PK studies in mice, rats, beagle dogs, mini-pigs.
At different time points (Typical time points: 30 Min; 1h; 3h; 6h; 12h; 24h; 32h;
48h and 96h), the presence of your drug or its metabolites will be searched and
analyzed in different organs (Liver; Spleen; Lung; Heart; Brain; Intestine;
Adipose tissues; Skin; Bone; Serum; Urine, etc.).
16). Mechanisms of actions studies
- Topoisomerases I & II, required during DNA replication, transcription
and homologous recombination;
- Cell cycle analysis Cells, stained with BrdU (Bromodeoxyuridin) and IP
(iodide propidium);
- Specific biomarkers by ICH Proliferation marker, Ki-67; angiogenesis
marker, CD-31, T cell infiltrations in tumors (CD4+ or CD8+), hypoxia,
etc.;
- Apoptosis analysis: Cells labeled with Annexin V and IP. Doublestained cells analyzed by FACScan.
17). Complete histological analysis and/or with experts’ interpretations
-
Tissues fixation in 4% Formalin;
Frozen tissues;
Paraffin-embedded or frozen sections;
H&E and/or immuno-staining.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
17/20
Confidential
Paraffin-embedding
Put into cassettes
Microtome cutting
Immuno-staining:
T cell infiltration stained with CD4 & CD8
antibodies.
Necrotic area inside tumors, with H&E
staining
18). Other specific studies upon request
Cellvax is also able to provide customized studies according to your specific needs in
order to fully satisfy the specific needs of our customers.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
18/20
Confidential
- HSV-1 and HSV-2 infection models in mice;
- Diabetic models:
- In vitro models;
- In vivo model for Type I diabetes;
- In vivo model for Type II diabetes.
- Parkinson diseases:
- In vitro models;
- In vivo models.
- Ascite production:
Ascite production in mice by administration of the incomplete Freund's adjuvant.
VI. Why contact us?
 Expertise of our founder and operational teams;
 Complementary and extensive biological tests;
 Reactivity and efficiency of services;
 Confidentiality and experimental procedures with Quality Insurance manager;
 State of the art animal facility with rodents and non-rodents;
 Access to a network of public and private laboratories;
 Continuous improvement of our tests in order to be more competitive;
 Our services allow to speed up the development of your drug candidates;
 Our services allow to valorize drug potential in several pathologies;
 Our services allow decreasing your cost of drug development;
 Support of external marketing.
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
19/20
Confidential
VII. Business development
The will to collaborate
Cellvax is a preclinical service company with strong expertise mainly in
Oncology and Osteoarthritis fields. Our interactive collaborations allow
accelerating the development of your drug candidates.
Cellvax has a strong will to collaborate with public laboratories, biotech and/or
with pharmaceutical companies which develop novel compounds. These
collaborations could be very enriching and allow speeding up the development
of your drug candidates.
Partnering strategy
Cellvax is also seeking to establish close collaboration and/or partnership to
develop or co-develop innovating compounds with a greater speed and less cost.
VIII. State of the art animal facility
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>
20/20
Confidential
IX. Contact Information


E-mail:
Phone:


Fax:
Web site:

Mailing address:
Cellvax Laboratory facility
Bâtiment Marcenac, aile Est,
Ecole Nationale Vétérinaire d’Alfort
7, avenue du Général de Gaulle
94704 Maisons Alfort cedex,
France.
<[email protected]>
+ 33 (0) 1 43 76 32 65;
Mobile: + 33 (0) 6 71 43 47 51.
+ 33 (0) 1 43 76 32 65.
<www.cellvax-pharma.com>
Thank you for your attention !
From R&D via animal to man!
Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de
Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0)
1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>